immatics biotechnologies GmbH

Company

    • Company type:
      • Manufacturer
    • Year founded:
    • not available
    • Employees (at the site):
    • not available
    • Turnover range:
    • not available
    • Products/services:
    • immatics has a good track record of success: We are optimistic that we have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severe side effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. We are currently working on the development of new substances for a number of specific cancer types. Our most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer.

    • Core competencies:
    • not available

    • Language skills:
    • English
    • Key Tech / section:
      • Biotechnology: Therapeutic drug development
    • Certification:
    • not available

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Dr. Rainer Kramer (Mr.)
      - Management

      Paul Higham (Mr.)
      - Management